Publications by authors named "D Strumberg"

Claim this Profile
T
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia von Tresckow, Dirk Strumberg

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The neuroepithelial origin of ovarian carcinomas explained through an epithelial-mesenchymal-ectodermal transition enhanced by cisplatin.
David Díaz-Carballo, Ayesha Safoor, Sahitya Saka, Adrien Noa-Bolaño, Flevy D'Souza, Dirk Strumberg

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Dirk Strumberg

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Thorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, Harald Schmalenberg, Dirk Strumberg

Int J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.
David Díaz-Carballo, Sahitya Saka, Ali H Acikelli, Ekaterina Homp, Julia Erwes, Dirk Strumberg

Commun Biol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis